WESTON, Mass., Sept. 6, 2024 /PRNewswire/ — Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today that its LungVision® system will be featured in the scientific programming at the 2024 European Respiratory Society (ERS) Congress taking place September 7 – 11 in Vienna, Austria.
LungVision® uses artificial intelligence (AI) to transform any C-arm fluoroscope into an advanced intraoperative tomographic imaging system with augmented fluoroscopic guidance. LungVision’s real-time imaging gives bronchoscopists the confidence to biopsy from small pulmonary lesions with greater speed and precision, maximizing the likelihood for earlier-stage cancer detection and improved lung cancer survival.
Key Presentation:
Title: First European experience with C-arm based tomography for the diagnosis of peripheral nodules
Speaker: Dr. Martina Ferioli
Location: Room PS-31, Board No. 13
Date: Sunday, September 8, 12:30 – 14:00 CEST
Abstract and full session details can be found at live.ersnet.org/programme/presentation/560354
Body Vision, in partnership with MOSS S.p.A., will also be exhibiting throughout ERS at booth A6.03.
Body Vision will be showcasing the latest software update for LungVision®. LungVision® v2.27 introduces Body Vision’s latest AI Tomo® imaging algorithm with a larger field of view, improves the reach and fidelity of the virtual bronchoscopy in peripheral airways, and provides an improved pathway planning experience.
About Body Vision Medical
Body Vision Medical believes in saving lives through the democratization of innovative medical technology and the Quintuple Aim is at the heart of everything that we do. LungVision® provides AI-powered real-time image guidance to address the clinical need for early, definitive lung cancer diagnosis and to enable effective treatment of lung lesions via minimally invasive procedures.
Visit bodyvisionmedical.com to learn more and connect with us on LinkedIn.
Contact:
Victor Chan
+1.415.794.1053
info@bodyvisionmedical.com
SOURCE Body Vision Medical
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…